BriLife
Sign in to saveAlso known as IIBR-100, IIBR 100, rVSV-SARS-CoV-2-S
BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate. It was developed by the Israel Institute for Biological Research (IIBR). The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine. A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.
In the Vinony graph
Vinony's link graph records 1,278 inbound references to BriLife, and connects out to SARS-CoV-2, Gam-COVID-Vac and COVID-19 pandemic in Italy.
It sits within the topics Chemical pages without ChemSpiderID, Chemical pages without DrugBank identifier and Clinical trials related to COVID-19.
Vinony links it to 8 Wikipedia language editions.
Wikidata facts
- Country of origin
- Israel
- Manufacturer
- Israel Institute for Biological Research
- Image
- Reuven Rivlin with the first vaccinator in Phase B of the Israeli Vaccine of the Israeli Biological Institute, January 2021 (GPOABG 4045).jpg
Show 4 more facts
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate. It was developed by the Israel Institute for Biological Research (IIBR). The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine. A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.
== References ==
Excerpted from Wikipedia’s “BriLife” article, available under the CC BY-SA 4.0 licence.